Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formulary Controls, Substitutions Challenged By Connecticut In HMO Suit

Executive Summary

Connecticut's high-profile class action suit against Physicians Health Services contains a strong anti-formulary argument.

You may also be interested in...



Conn. Formulary Suit Dismissed: State Lacks Standing, Appeals Court Says

The state of Connecticut lacks the appropriate legal standing to challenge a managed care formulary under ERISA, a March 27 appeals court decision states

Conn. Formulary Suit Dismissed: State Lacks Standing, Appeals Court Says

The state of Connecticut lacks the appropriate legal standing to challenge a managed care formulary under ERISA, a March 27 appeals court decision states

Medco, PCS Among Firms Subpoenaed In Philadelphia PBM Investigation

The pressure on Rite Aid to divest PCS may create an opening for the Philadelphia U.S. attorney's ongoing investigation of the PBM industry.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel